Germline or somatic mutations in DNA damage repair (DDR) genes, such as BRCA2, CHEK2, ATM, RAD51D, BRCA1, and PALB2, have been described in around 20–25% of advanced prostate cancer patients, which involved in aggressive disease and poor outcomes in these patients [31]. This evidence concerns the gene ATM and Familial prostate cancer.